CHMP provides conditional reprieve for Fampyra
This article was originally published in Scrip
Executive Summary
After having first declined an opportunity to recommend Fampyra (fampridine) from Biogen Idec and Acorda Therapeutics, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the granting of market authorisation for use in improving the walking ability of adults with multiple sclerosis at its 16-19 May meeting. In January, the CHMP gave a negative opinion but at the request of Biogen Idec the committee re-examined its position.